ESMO Congress 2026Watching

UNION

4 reports2 sourcesupdated 2 days ago

Start here

No synthesis yet — start with the coverage timeline below.

Coverage timeline

Follow the coverage to see the different angles.

Oct 23

20:17
mp.weixin.qq.com
07:03
x.com
UNION: 3y EFS 91% vs 77% with SCRT/CAPOX/camrelizumab vs long-course CRT/CAPOX in rectal cancer. HR 0.33 (95% CI 0.15-0.71).
06:02
x.com
🚨UNION Trial🚨

Oct 19

07:00
x.com
#ESMO26 | 3530O UNION: Ph3 neoadjuvant SCRT followed by camrelizumab + chemo in locally advanced rectal cancer - 3y-EFS: 91.3% vs 77.4%, HR 0.33, p=0.0029 👉UNION is the first Ph3 …

Heat trend for this story

Heat now 8·Peak in the comparable set 23 (Oct 23 21:00)·Change over 24h in the comparable set -50%·Participants now 4

Participants counted4

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.